Tempus AI Inc. (NASDAQ: TEM) announced an expansion of its Next platform to include six new clinical scenarios across breast, colorectal, ovarian, prostate, and urothelial cancers. The company will present study results at the 2026 American Society of Clinical Oncology Annual Meeting.

The expansion comes alongside a multi-center prospective study evaluating the platform's implementation across 662 early-stage non-small cell lung cancer patients at six U.S. community health systems. The study measured biomarker testing rates before and after deploying the AI-enabled clinical decision support system.

According to the study results, the platform delivered testing rate increases of 24% for ALK, 18% for EGFR, and 13% for PD-L1 within 90 days of pathologic diagnosis. The company reported that 89% of treated patients received guideline-concordant therapy.

The Next platform analyzes unstructured electronic health record data to identify patients who have not received guideline-directed biomarker testing. The expanded version includes capabilities for precision medicine teams to develop targeted care gap programs.

"The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey," said Ryan Fukushima, CEO of Data and Apps at Tempus.

Tempus describes itself as a technology company that uses artificial intelligence to advance precision medicine. The company maintains what it characterizes as one of the world's largest libraries of multimodal data for healthcare applications.

The information is based on a company press release statement.